AU2022376939A1 - Combination therapy for treating abnormal cell growth - Google Patents

Combination therapy for treating abnormal cell growth Download PDF

Info

Publication number
AU2022376939A1
AU2022376939A1 AU2022376939A AU2022376939A AU2022376939A1 AU 2022376939 A1 AU2022376939 A1 AU 2022376939A1 AU 2022376939 A AU2022376939 A AU 2022376939A AU 2022376939 A AU2022376939 A AU 2022376939A AU 2022376939 A1 AU2022376939 A1 AU 2022376939A1
Authority
AU
Australia
Prior art keywords
inhibitor
cancer
raf
braf
dosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022376939A
Other languages
English (en)
Inventor
Sanjib CHOWDHURY
Silvia COMA
Jonathan A. Pachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of AU2022376939A1 publication Critical patent/AU2022376939A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022376939A 2021-10-28 2022-10-27 Combination therapy for treating abnormal cell growth Pending AU2022376939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272899P 2021-10-28 2021-10-28
US63/272,899 2021-10-28
PCT/US2022/078771 WO2023076991A1 (fr) 2021-10-28 2022-10-27 Polythérapie pour le traitement d'une croissance cellulaire anormale

Publications (1)

Publication Number Publication Date
AU2022376939A1 true AU2022376939A1 (en) 2024-05-02

Family

ID=86158717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022376939A Pending AU2022376939A1 (en) 2021-10-28 2022-10-27 Combination therapy for treating abnormal cell growth

Country Status (8)

Country Link
EP (1) EP4422617A1 (fr)
KR (1) KR20240095266A (fr)
CN (1) CN118510505A (fr)
AU (1) AU2022376939A1 (fr)
CA (1) CA3235499A1 (fr)
IL (1) IL312248A (fr)
MX (1) MX2024005024A (fr)
WO (1) WO2023076991A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024054591A1 (fr) * 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés
CN116570599B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合ly3009120的应用及药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668055B2 (en) * 2013-12-20 2020-06-02 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
JP6864990B2 (ja) * 2015-04-16 2021-04-28 日東電工株式会社 Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
EP3664851A4 (fr) * 2017-08-07 2021-05-19 Evol Science LLC Combinaisons pour le traitement du cancer
WO2021047783A1 (fr) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer

Also Published As

Publication number Publication date
WO2023076991A1 (fr) 2023-05-04
KR20240095266A (ko) 2024-06-25
EP4422617A1 (fr) 2024-09-04
CA3235499A1 (fr) 2023-05-04
IL312248A (en) 2024-06-01
MX2024005024A (es) 2024-05-13
CN118510505A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
EP4096671A1 (fr) Polythérapie pour le traitement d'une croissance cellulaire anormale
US20240115571A1 (en) Combination therapy for treating abnormal cell growth
CA3152805A1 (fr) Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer
WO2023076991A1 (fr) Polythérapie pour le traitement d'une croissance cellulaire anormale
WO2023147297A2 (fr) Polythérapie pour le traitement d'une croissance cellulaire anormale
EP4444310A2 (fr) Polythérapie pour le traitement d'une croissance cellulaire anormale
US20230201198A1 (en) Methods of treating abnormal cell growth
IL312469A (en) Methods for treating abnormal cell proliferation
WO2022015736A9 (fr) Polythérapie pour le traitement d'une croissance cellulaire anormale
WO2023235356A1 (fr) Polythérapie pour le traitement d'une croissance cellulaire anormale
JP2024540015A (ja) 異常な細胞成長を処置するための併用療法
CN117729923A (zh) 治疗异常细胞生长的联合疗法